The expected August 22 FDA decision is now delayed three months. The filing moves the PDUFA target date to November 22, 2026, after the FDA classified Capricor’s amendment as a major amendment and accepted it for review. 〔0〕 This is a timing negative versus the standing expectation of an imminent approval decision, but it is not a rejection or a new complete response letter.
The company is trying to reshape the approval question around upper-limb preservation. Capricor submitted 24-month open-label data and additional robustness analyses while asking the FDA to evaluate a refined indication focused on upper-limb function, the primary endpoint of HOPE-3. 〔1〕 That narrows the commercial and regulatory claim, suggesting the original broader framing was not the cleanest path through review.
The clinical package still has a usable approval argument, but the filing does not remove regulatory uncertainty. Management says HOPE-3 met its primary endpoint with a statistically significant upper-limb benefit. 〔2〕 However, the need for a major amendment after the July advisory process means the FDA is still reassessing how the evidence supports the label, rather than simply processing a routine final review.
Net read: the delay is offset by a potentially more defensible indication, leaving the event genuinely two-sided. The FDA’s willingness to accept the added evidence and cite significant unmet need keeps the application alive, while the three-month delay pushes out the catalyst and confirms that approval is not yet a near-certain administrative step. The key change is not new efficacy data alone; it is the shift from seeking a broader DMD claim toward an upper-limb-focused approval decision.
Read the original 8-K on SEC EDGAR ↗